



## Skysona (elivaldogene autotemcel)

### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

Skysona (elivaldogene autotemcel)	1
Summary	1
Definitions	2
Medical Necessity Criteria for Initial Clinical Review	3
Initial Indication-Specific Criteria	3
Cerebral Adrenoleukodystrophy	3
Experimental or Investigational / Not Medically Necessary	4
Applicable Billing Codes	5
References	6
Clinical Guideline Revision / History Information	6

### Summary

Skysona (elivaldogene autotemcel) is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Early, active cerebral adrenoleukodystrophy refers to asymptomatic or mildly symptomatic (neurologic function score, NFS  $\leq$  1) boys who have gadolinium enhancement on brain magnetic resonance imaging (MRI) and Loes scores of 0.5-9.

Skysona (elivaldogene autotemcel) is a one-time gene therapy, made specifically for each individual, using the person's own blood stem cells. It works by adding functional copies of the *ABCD1* gene to cells. CALD is a rare genetic condition typically found in young males, caused by *ABCD1* gene mutations on the X chromosome, leading to build up of very long chain fatty acids (VLCFAs) in the brain that cause damage to the brain by destroying the protective covering around nerve cells - which can be seen on magnetic resonance imaging (MRI) of the brain. Skysona (elivaldogene autotemcel) may slow the nerve damage in early, active cerebral adrenoleukodystrophy. Functional copies of the *ABCD1* gene added by Skysona (elivaldogene autotemcel) may help the body break down the VLCFAs, slowing the progression of damage to the brain as well as decline in neurologic function.

Prior to Skysona (elivaldogene autotemcel), there have been no FDA-approved treatments for CALD in the United States (US). Allogeneic hematopoietic stem cell transplant (allo-HSCT) has been the standard of care for the past two decades for boys with early, active CALD. Allo-HSCT carries significant risks, including infection and graft-versus-host disease

Skysona (elivaldogene autotemcel) has a boxed warning for increased risk of hematological malignancies, including life-threatening cases of myelodysplastic syndrome and acute myeloid leukemia. All members treated with Skysona (elivaldogene autotemcel) should be monitored closely via complete blood counts (at least every 3 months) and through assessments for evidence of clonal expansion or predominance at least twice annually for the first year, and annually thereafter. Bone marrow evaluations should be considered as clinically indicated.

## Definitions

"Allogeneic" is when healthy stem cells are donated (harvested) from someone else's bone marrow.

"Autologous" is when healthy stem cells are donated (harvested) from a person's own body, then frozen and stored before starting radiation or chemotherapy. The harvested stem cells are thawed and put back into the individual's body after treatment.

"Bone marrow transplant" also known as "stem cell transplant" is a procedure that involves getting bone marrow cells from a donor (usually a sibling with similar genes, without or with a milder form of the condition/mutation).

"Early, active cerebral adrenoleukodystrophy" refers to asymptomatic or mildly symptomatic (neurologic function score, NFS  $\leq 1$ ) boys who have gadolinium enhancement on brain magnetic resonance imaging (MRI) and Loes scores of 0.5-9.

"Neurologic Function Score (NFS)" is a 25-point composite scale that focuses on 15 domains of neurologic function, is traditionally used to evaluate the clinical status of CALD patients. A score of 0

indicates absence of clinical signs of cerebral disease (i.e., asymptomatic), and higher scores correspond to increasing severity of neurological dysfunction.

"Loes score" is an adrenoleukodystrophy (ALD) MRI score, which rates the severity of white matter lesions and ranges from 0 (normal) – 34 (abnormal), based on location and extent of demyelination, as well as presence/ absence of focal and/or global atrophy. A score of 0 indicates a normal MRI (i.e., no cerebral disease), and higher scores indicate increased severity of cerebral lesions.

"Gadolinium", also called "contrast," is a large, chemical compound that is injected into a person's vein during an MRI scan.

"Gadolinium-enhanced magnetic resonance imaging (MRI) scan" is a technique used to determine the age of a lesion (whether active inflammation is recent). Gadolinium enhancement on brain MRI has been associated with breakdown of the blood-brain barrier and is thought to represent progressive and active inflammatory demyelination associated with increased risk of rapid disease progression.

## Medical Necessity Criteria for Initial Clinical Review

### Initial Indication-Specific Criteria

#### Cerebral Adrenoleukodystrophy

The Plan considers Skysona (elivaldogene autotemcel) medically necessary when ALL of the following criteria are met:

1. Prescribed by or in consultation with a neurologist, endocrinologist, or hematologist-oncologist;  
*AND*
2. The member meets ALL of the following:
  - a. Is a male between 4-17 years of age; *and*
  - b. Has a diagnosis of early, active cerebral adrenoleukodystrophy (CALD) as defined by BOTH of the following:
    - i. Elevated very long chain fatty acids (VLCFA) values; *and*
    - ii. Brain magnetic resonance imaging (MRI) demonstrating BOTH of the following:
      1. Loes score between 0.5 and 9 on the 34-point scale; *and*
      2. Gadolinium enhancement (GdE+) on MRI of demyelinating lesions; *and*
  - c. Neurologic Function Score (NFS) less than or equal to ( $\leq$ ) 1; *AND*
3. The member meets ALL of the following::
  - a. No available and willing 10/10 HLA-matched sibling donor (excluding female heterozygotes); *or*
  - b. No cardiac compromise as evidenced by left ventricular ejection fraction <40 percent (%); *or*

- c. No clinically significant uncontrolled, active bacterial, viral, fungal, parasitic, or prion associated infection; *or*
- d. No contraindications to the (myeloablative and lymphodepleting) conditioning regimen; *or*
- e. No hepatic compromise as evidenced by:
  - i. Aspartate transaminase (AST) value greater than ( $>$ )  $2.5 \times$  upper limit of normal (ULN); *or*
  - ii. Alanine transaminase (ALT) value  $>2.5 \times$  ULN; *or*
  - iii. Total bilirubin value  $>3.0$  milligram per deciliter (mg/dL), except if there is a diagnosis of Gilbert's Syndrome and the member is otherwise stable; *or*
- f. No hematological compromise as evidenced by:
  - i. Peripheral blood absolute neutrophil count (ANC) count  $<1500$  cells/ cubic millimeter ( $\text{mm}^3$ ); *and either*:
    - 1. Platelet count  $<100,000$  cells/ $\text{mm}^3$ ; *or*
    - 2. Hemoglobin  $<10$  gram per deciliter (g/dL); *or*
- g. Not positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1, HIV-2), hepatitis B virus (HBV), hepatitis C (HCV), or human T lymphotropic virus 1 (HTLV-1); *or*
- h. No prior treatment with HSCT or gene therapy; *or*
- i. No renal impairment, defined as creatinine clearance  $\leq 50$  mL/min; *AND*
- 4. Dose is within the recommended range of:
  - a. Minimum of  $5.0 \times 10^6$  CD34+ cells/kg; *and*
  - b. Maximum of  $38.2 \times 10^6$  CD34+ cells/kg.

If the above prior authorization criteria are met, the requested product will be authorized for a one-time administration at the recommended dose.

#### Experimental or Investigational / Not Medically Necessary

Skysona (elivaldogene autotemcel) for any other indication is *not covered* by the Plan, as it is considered experimental or investigational. Non-covered indications include, but are not limited to, the following:

- For CALD secondary to head trauma. Skysona (elivaldogene autotemcel) has not been studied in this population.
- For individuals whose sex is not male, unless the prescriber is able to provide information that the requested agent is medically appropriate for the member's sex.
- To prevent the development of or treat adrenal insufficiency due to adrenoleukodystrophy.
- Re-treatment [Skysona (elivaldogene autotemcel) is indicated for one-time single-dose intravenous use only].

## Applicable Billing Codes

Table 1	
CPT/HCPCS Codes for cerebral adrenoleukodystrophy considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
C9399	Unclassified drugs or biologicals
J3590	Unclassified biologics

Table 2	
ICD-10 diagnosis codes considered medically necessary for cerebral adrenoleukodystrophy with Table 1 (CPT/HCPCS) codes if the criteria are met:	
<i>Code</i>	<i>Description</i>
E71.520	Childhood cerebral X-linked adrenoleukodystrophy
E71.521	Adolescent X-linked adrenoleukodystrophy

## References

1. Bougnères P, Hacein-Bey-Abina S, Labik I, et al. Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. *Hum Gene Ther.* 2021;32(19-20):1260-1269. doi:10.1089/hum.2021.053
2. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. *Science.* 2009;326(5954):818-823. doi:10.1126/science.1171242
3. Cellular, Tissue, and Gene Therapies Advisory Committee June 9-10, 2022 Meeting, FDA, available: <https://www.fda.gov/advisory-committees/advisorycommittee-calendar/cellular-tissue-and-gene-therapies-advisory-committeejune-9-10-2022-meeting-announcement-06092022>.
4. Duncan CN, Bledsoe JR, Grzywacz B, et al. Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. *N Engl J Med.* 2024 Oct 10;391(14):1287-1301. doi: 10.1056/NEJMoa2405541.
5. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. *N Engl J Med.* 2017;377(17):1630-1638. doi:10.1056/NEJMoa1700554

6. Eichler F, Duncan CN, Musolino PL, et al. Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy. *N Engl J Med*. 2024 Oct 10;391(14):1302-1312. doi: 10.1056/NEJMoa2400442.
7. Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. *Orphanet J Rare Dis*. 2012;7:51. Published 2012 Aug 13. doi:10.1186/1750-1172-7-51
8. Kemper AR, Brosco J, Comeau AM, et al. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. *Genet Med*. Epub 2016 Jun 23.
9. Mallack EJ, Turk BR, Yan H, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. *J Inher Metab Dis* 2021;44:728-39.
10. Mallack EJ, van de Stadt S, Caruso PA, et al. Clinical and radiographic course of arrested cerebral adrenoleukodystrophy. *Neurology*. 2020;94(24):e2499-e2507. doi:10.1212/WNL.0000000000009626
11. Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. *Blood* 2011;118:1971-8.
12. Skysona (elivaldogene autotemcel) [prescribing information]. Somerville, MA: Bluebird Bio Inc; August 2025.

#### Clinical Guideline Revision / History Information

Original Date: 12/08/2022

Reviewed/Revised: 12/14/2023, 12/19/2024, 01/01/2026